MGNX News and Press, MacroGenics Inc. From 01/23/23

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Summary MacroGenics' one approved therapy is a dud. Its pipeline is mediocre. MacroGenics has a secret sauce that moderates its deficits, however its longer-term prospects are highly uncertain.            . This is my first look at MacroGenics ( ...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the company will participate in the 41 st Annua...

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and M...

Summary After the FDA's approval of Tzield and with better-than-expected pricing, we are upgrading to a Buy rating. PRVB's pricing and approval bode well for the stock and de-risk owning it; however, we are neutral around the Q1-Q2 sales print due to uncertainty around market access. ...

Summary Zai Lab Limited is a relative new entrant to the Chinese pharma space and has multiple approvals and a large clinical pipeline. Founder Samantha Du seems willing and capable at driving commercialization partnerships with foreign entities. Also, the in-house pipeline is set t...

Shares of MacroGenics (NASDAQ: MGNX) were down more than 18% in early trading on Tuesday. The stock closed at $6.37 on Monday. On Tuesday, it opened at $5.99, then fell as low as $5.05 in the couple of hours of trading. The stock has a 52-week high of $19.73 and a low of $2.13 and i...

ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announce...

On a generally uninspiring day for the market, biotech MacroGenics (NASDAQ: MGNX) was a standout performer. The company's share price gained nearly 4% in value against a slumping S&P 500 index, on a new and quite bullish take from an analyst. That analyst was BMO Capital...